The king of cancer therapies, Roche, has raised the bar again following its very recent June 2012 approval of Perjeta, a first-ever monoclonal antibody therapy specifically targeting HER-2-positive metastatic breast cancer....
Contact us to learn the benefits of becoming a Lux member.
Or call us now
For North America (Boston Headquarters)
+1 (617) 502-5300
For EMEA (Amsterdam)
+31 20 280 7900
For APAC (Singapore)